API Synthesis and Manufacturing, Small Molecule

Biocatalysis, chemocatalysis, and other chiral technologies continue to attract the investment dollars of CMOs and fine-chemical companies.

Direct dosing APIs during R&D studies can reduce the overall testing time of a drug candidate by allowing for a greater throughput of compounds through the R&D department.

The increasing cost of crucial manufacturing input factors, such as energy and raw materials, has been a severe threat to several companies.

As contract manufacturers and fine-chemical suppliers gather for CPhI/ICSE, effective strategies for technology differentiation are key in an increasingly competitive environment.

Recently, there have been many innovations in the latest techniques and technologies in API purification. In particular, the trend to single-use systems has had a significant impact on processes.

O-arylation and O-alkylation, a one-pot protein synthesis, a combined approach in continued and chemocatalysis, and green-chemistry applications are the target of some recent advances in API synthesis.

The solid form of an API plays a crucial role in drug quality, and advancing methods for screening, detection, and characterization is key.

Effective containment in API and drug-product manufacturing encompasses a variety of process, equipment, and operational issues.

Approaches in using small-molecule and peptide synthesis offer promise in widening the scope of drug candidates.

Chemocatalytic and biocatalytic routes play an important role in improving the manufacture of intermediates and active pharmaceutical ingredients.

The power of emerging markets is reflected in the pharma's sales and production positions.

Contract manufacturers strengthen their toolboxes and partnerships as they navigate the changing drug-development model.

Approaches in cyclization, palladium-catalyzed cross couplings, fluorination, and natural product synthesis help to optimize routes for select drugs.

Abuse-deterrent combination drugs represent a niche area in formulation development.

Industrial and academic partnerships forge new territory in solid-state chemistry.

A recently released industry guide outlines a science- and risk-based approach to control the risk of cross-contamination.

Pharmaceutical Technology gains insight into approaches for producing aromatic amines.

Chemocatalytic and biocatalytic approaches in asymmetric synthesis help provide a pathway for producing single-enantiomer drugs.

Green chemistry in pharmaceutical development often centers around approaches in the synthesis of the active ingredient, but green-chemistry techniques also can be applied to drug-product manufacturing, formulation development, and drug delivery.

Chemocatalysis and biocatalysis are important elements of an effective strategy for improving yield and stereoselectivty.

Emerging markets remain an important element in the strategies of pharmaceutical companies and their suppliers.

As contract manufacturers and drug companies meet at Informex, the stage is set for the latest in pharmaceutical chemical development.

Leading experts share insight on polymorphism and crystallization.

Functionalized supramolecular catalysts and an enantioselective route to unnatural amino acids are some recent developments.

New nanotechnology-based delivery systems offer promise in drug delivery, particularly for anticancer therapeutics.

Select contract manufacturing organizations roll out expansions for production of active pharmaceutical ingredients and intermediates.

Biologics enhance their positions amidst slowing growth in the global and US markets.

High-potency manufacturing of active pharmaceutical ingredients is a growing and specialized capability.

Contract manufacturers deploy a business model using operations in the US and Western Europe with facilities in Asia.

The pharmaceutical majors forward projects in biocatalysis, solvent replacement, and other approaches in green chemistry.